Avecho Biotechnology Ltd has released a press release.
December 2022 Quarterly Activities Report & Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Story so far
Earlier from Avecho Biotechnology
- Athenex submits Avechos phytonadione to FDA pre-IND
- Avecho receives ethics approval for Phase III CBD trial
- AVE signs development agreement with Perrigo
- September 2022 Quarterly Activities Report & Appendix 4C
- Increased CBD absorption in dogs vs commercial comparator
Later from Avecho Biotechnology
- Clinical CBD program expands with the Lambert Initiative
- Entitlement Offer to raise $11m for Phase 3 clinical trial
- Prospectus
- Investor Presentation
- March 2023 Quarterly Activities Report & Appendix 4C
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology